In the News: Mar 12–19

Atrial Fibrillation Patients May Live Longer Due to Exercise

A recent Washington Post article suggests that, despite the cardiac exertion exercise causes, physically active atrial fibrillation (AF) patients may live longer than those who remain sedentary. People living with AF experience a drop in blood pressure during activities that require physical exertion, which leads to feeling faint and breathless, but a new study found moderate exercise, such as brisk walking for 30 minutes most days of the week, could help AF patients live longer.

The study monitored 1,000 adults, aged approximately 72 years, with AF over a 7- to 9-year period and found participants who exercised regularly were approximately 45% less likely to die of cardiovascular-related causes. Metabolic equivalent of task (MET) measures were used to score participant’s exercise intensity levels, and each additional MET hour per week was associated with a 15% lower risk of cardiovascular-related death.

AF is very common in the US aging population, impacting nearly 5 million people—and this number is anticipated to double over the next 30 years. Existing treatment methods, including medical procedures and therapies, should be considered as part of an overarching arrhythmia and stroke management strategy. To learn more about key considerations in developing comprehensive AF programs, please read the Sg2 FAQ Atrial Fibrillation Programs.

New AI Will Aid Socioeconomic Health Challenges

A recent Becker’s Hospital Review article highlights Jvion’s new clinical artificial intelligence (AI) that detects gaps in patients’ care related to socioeconomic barriers and suggests potential investments hospitals and other health care organizations can make in the community to benefit these patients.

This technology can work for large patient populations as well as individual cases, offering solutions to consider for individualized interventions. Though this technology is based on de-identified patient data, it can produce actionable insights related to patients’ socioeconomic factors, which has proven challenging. As Jvion’s clinical AI technology leverages socioeconomic, environment and behavioral data, it can hopefully help drive better outcomes for the community.

AI-based solutions have quickly moved from being a novelty to providing novel solutions to complex health care challenges. And while these solutions may only be scratching the surface of the value they will deliver over time, this exponential improvement has positioned AI to disrupt nearly every aspect of the clinical enterprise. To learn more about how to integrate AI into various clinical areas, please view Sg2’s on-demand webinar Disrupters to Watch in 2020.

Providers Concerned About Increase in Alzheimer Disease Cases

A recent FierceHealthcare article highlighted that the number of aged 65 and over patients with Alzheimer disease and dementia may almost triple by 2050. This increase concerns many primary care providers, as they believe the medical profession is not prepared to meet the demand.

Even though the number of patients with Alzheimer disease and dementia is set to increase in the next 5 years, nearly one-third of primary care providers report they are uncomfortable answering patient questions about Alzheimer disease or other dementias. This poses a problem, as providers are expected to know the latest developments and practices around dementia care for patients and caregivers. In addition, the dementia care specialist shortage adds to an already strained workforce.

As Alzheimer disease and dementia continue to grow across the aging population, providers need to innovate care delivery in this space. Currently, new care models aim to keep patients at home or living independently while increasing quality of life and reducing costs associated with residential care. Please read the Sg2 FAQ Alzheimer and Dementia Care Landscape to learn more about innovative care models and different ways providers are currently implementing new programs to address the rise of these cases.

  • Share
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn

Tags: , , , , , , ,